Compare DexCom, Inc. (DXCM) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Charles Schwab Corporation Common Stock — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while Charles Schwab Corporation Common Stock trades at $103.15 (market cap $178.77B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 6.4× DexCom, Inc.'s market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SCHW | |
|---|---|---|
Market Cap | $28.06B | $178.77B |
Sector | Health | Financials |
52-Week High | $89.53 | $107.21 |
52-Week Low | $54.84 | $85.35 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Charles Schwab (SCHW) trades at $101.10, down 1.25% today, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential near-term overbought conditions. Recent financial performance demonstrates robust revenue growth to $23.92 billion in 2025 and net income margin expansion to 37.99%, supported by strong trading activity and asset management fees.
The outlook remains positive with analyst consensus pointing to 25.9% upside potential to $123.71. Key catalysts include continued earnings growth and strong retail trading activity, while risks involve interest rate sensitivity and market volatility. With 58% of analysts maintaining buy ratings and improving cash flow trends, SCHW presents a compelling investment case for growth-oriented investors despite current valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
